This new semaglutide dose helped nearly half of patients lose 20% body weightThis new semaglutide dose helped nearly half of patients lose 20% body weight
The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment Read More
This new semaglutide dose helped nearly half of patients lose 20% body weightThis new semaglutide dose helped nearly half of patients lose 20% body weight
The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment […]
Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad SayPick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say
(MedPage Today) — A new treatment algorithm from the European Association for the Study of Obesity (EASO) recommends opting for semaglutide (Wegovy) or tirzepatide (Zepbound) first when “substantial” weight loss is needed in a patient. The two… (MedPage Today) — A new treatment algorithm from the European Association for the Study of Obesity (EASO) Read More
Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidanceSemaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) published in the journal Nature Medicine. Semaglutide or tirzepatide should be the Read More
GLP-1 Receptor Agonists and Cancer Risk in Adults With ObesityGLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity. This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity.
Once-Monthly GLP-1 Shot? Mangos for Blood Sugar Control; New Acromegaly TreatmentOnce-Monthly GLP-1 Shot? Mangos for Blood Sugar Control; New Acromegaly Treatment
(MedPage Today) — The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of up to 14.1% by week 28 with class-leading tolerability in a phase IIb trial, said developer Metsera… (MedPage Today) — The investigational GLP-1 receptor agonist MET-097i, which may be able Read More
Best Practices Needed for GLP-1 Drug Prescribing in Sleep Apnea, Experts SayBest Practices Needed for GLP-1 Drug Prescribing in Sleep Apnea, Experts Say
(MedPage Today) — At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA), particularly tirzepatide (Zepbound), which late last year became the first FDA-approved drug for… (MedPage Today) — At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists Read More
GLP-1 Drugs Show Benefits in Lupus Patients With DiabetesGLP-1 Drugs Show Benefits in Lupus Patients With Diabetes
(MedPage Today) — Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk of serious cardiovascular and kidney diseases when they took GLP-1 receptor agonists compared with… (MedPage Today) — Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus Read More
GLP-1 Scripts for Seniors? Expect Prior AuthorizationsGLP-1 Scripts for Seniors? Expect Prior Authorizations
(MedPage Today) — Hurdles to receive GLP-1 receptor agonists rose sharply in the last several years for Medicare Part D beneficiaries, a national study showed. Nearly all plans instituted prior authorization from 2020 to 2025, and many started… (MedPage Today) — Hurdles to receive GLP-1 receptor agonists rose sharply in the last several years Read More
Pill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggestsPill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggests
A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity. A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 Read More